Why the study?
Patients with AF and AFL with ESRD were historically excluded from pivotal DOAC trials, and real-world anticoagulation prescribing trends in this setting remain poorly described.
What are the real-world prescribing trends for apixaban in patients with atrial fibrillation and atrial flutter with end-stage renal disease?
Observational
Yes
What are the real-world prescribing trends for apixaban in patients with atrial fibrillation and atrial flutter with end-stage renal disease?
Answers are grounded in this paper and cite their sources.
Analysis highlights evolving anticoagulation practices in patients with atrial fibrillation and end-stage renal disease, suggesting shifts in clinical guidance.
Patients with atrial fibrillation (AF) and atrial flutter (AFL) with end-stage renal disease (ESRD) have historically been excluded from pivotal DOAC trials, and earlier guidelines discouraged their use. The 2023 ACC/AHA/ACCP/HRS guideline cautiously endorsed apixaban or warfarin as reasonable options (Class 2b), yet real-world prescribing trends for anticoagulation in this setting remain poorly described.
No takes yet. Share an insight, caveat, or question.
Abumuhfouz et al. (2026) conducted an observational in Atrial fibrillation and atrial flutter with end-stage renal disease. Apixaban was evaluated on Prescribing trends for anticoagulation. Apixaban use is rising for atrial fibrillation and atrial flutter in patients with end-stage renal disease, reflecting a practice shift over a 5-year period.
Synapse has enriched 10 related papers. Consider them for comparative context: